Back to top
more

Elite Pharmaceuticals (ELTP)

(Delayed Data from OTC)

$0.50 USD

0.50
1,948,352

+0.06 (13.18%)

Updated Nov 1, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Fiscal Year End for Elite Pharmaceuticals Inc falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Assets          
Cash & Equivalents 7 8 9 3 1
Receivables 19 3 3 4 4
Notes Receivable 0 0 0 0 0
Inventories 13 10 7 5 4
Other Current Assets 1 1 1 0 1
Total Current Assets 40 22 19 12 10
Net Property & Equipment 10 10 6 7 7
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 22 2 2 0 0
Intangibles 6 6 7 7 7
Deposits & Other Assets 1 0 1 1 0
Total Assets 84 41 35 26 25
Liabilities & Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Notes Payable 4 0 0 0 1
Accounts Payable 3 2 1 1 2
Current Portion Long-Term Debt 0 0 0 0 1
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 5 5 5 4 5
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 13 8 7 6 9
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 3 4 1 2 2
Non-Current Capital Leases 1 0 0 0 0
Other Non-Current Liabilities 6 1 1 2 4
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 26 12 10 10 14
Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Preferred Stock 0 0 0 0 14
Common Stock (Par) 1 1 1 1 1
Capital Surplus 173 165 165 164 150
Retained Earnings -116 -137 -140 -149 -154
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 58 29 25 16 11
Total Liabilities & Shareholder's Equity 84 41 35 26 25
Total Common Equity 58 29 25 16 -3
Shares Outstanding 1,068.20 1,013.90 1,011.20 1,009.10 840.40
Book Value Per Share 0.05 0.03 0.02 0.02 0.00

Fiscal Year End for Elite Pharmaceuticals Inc falls in the month of March.

All items in Millions except Per Share data.

9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Assets          
Cash & Equivalents -99,999 8 7 6 9
Receivables NA 20 19 16 11
Notes Receivable NA 0 0 0 0
Inventories NA 14 13 14 15
Other Current Assets NA 0 1 1 0
Total Current Assets NA 43 40 37 35
Net Property & Equipment NA 11 10 10 10
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 22 22 20 19
Intangibles NA 7 6 6 6
Deposits & Other Assets NA 1 1 0 0
Total Assets NA 88 84 75 71
Liabilities & Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Notes Payable NA 0 4 0 4
Accounts Payable NA 3 3 3 4
Current Portion Long-Term Debt NA 4 0 4 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 6 5 12 11
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 14 13 19 19
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 3 3 3 3
Non-Current Capital Leases NA 1 1 0 0
Other Non-Current Liabilities NA 6 6 3
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 30 26 28 26
Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 1
Capital Surplus NA 173 173 165 165
Retained Earnings NA -116 -116 -120 -120
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 58 58 46 45
Total Liabilities & Shareholder's Equity NA 88 84 75 71
Total Common Equity 0 58 58 46 45
Shares Outstanding 1,068.20 1,068.20 1,068.20 1,017.70 1,013.90
Book Value Per Share 0.00 0.05 0.05 0.05 0.04